Emphysema
Drug research and approvals for emphysema: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 66 studies of emphysema are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 1 approved and 6 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 66
- Trials authorized in Canada: 3
- FDA orphan approvals: 1
- EU medicines: 1
Recruiting Now
Newest start dates first, of 66 recruiting on ClinicalTrials.gov ↗- A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With…NCT07850076 · Phase 1 / Phase 2 · CRISPR Therapeutics · starts Dec 1, 2026
- Chronic Respiratory Disease Participant Engagement StudyNCT07924462 · Not reported · Richmond Research Institute · starts Nov 1, 2026
- Xenon MRI to Evaluate Changes to Lung Function Following Bronchoscopic Treatment of Air Trapping in EmphysemaNCT07896902 · Early Phase 1 · Apreo Health, Inc. · starts Oct 1, 2026
- Clinical Utility of LIBS Multi-Element Imaging and the IFF Algorithm in Chronic Lung DiseasesNCT07597187 · Not reported · University Hospital, Grenoble · starts Oct 1, 2026
- Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza…NCT07326592 · Phase 4 · CSL Behring · starts Sep 29, 2026
- A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease…NCT07759245 · Phase 2 · Eli Lilly and Company · starts Aug 7, 2026
- IBS-Oriented CDED Versus Low FODMAP Diet for Irritable Bowel SyndromeNCT07707635 · Not applicable · Ariel University · starts Jul 19, 2026
- A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15%…NCT07555483 · Phase 3 · Grifols Therapeutics LLC · starts May 5, 2026
- A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)NCT07227207 · Phase 1 / Phase 2 · Tessera Therapeutics, Inc. · starts Apr 21, 2026
- A Multi Center Study Testing a New Implant for Adults With Severe EmphysemaNCT07119229 · Not applicable · Pulmair Medical, Inc. · starts Mar 25, 2026
Drug Pipeline
12 approved, 1 in phase 3, 7 in phase 2; from ChEMBL's drug indications, furthest stage reached for this conditionApproved: Salmeterol, Arformoterol, Formoterol, Budesonide, Fluticasone propionate, Aclidinium, Tiotropium, Ipratropium, Vilanterol, Indacaterol, Umeclidinium, Olodaterol
- Basiliximab
- Phase 3 Interleukin-2 receptor inhibitor
- Doxycycline anhydrous
- Phase 2 Matrix metalloproteinase 7 inhibitor
- Ibuprofen
- Phase 2 Cyclooxygenase inhibitor
- Isotretinoin
- Phase 2 Retinoic acid receptor agonist
- Tretinoin
- Phase 2 Retinoic acid receptor agonist
- Sildenafil
- Phase 2 Phosphodiesterase 5A inhibitor
- Belimumab
- Phase 2 Tumor necrosis factor ligand superfamily member 13B inhibitor
How Its Trials Ended
323 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 84 whose ending is known, 37% met their primary endpoint, 6% missed it and 57% stopped early.
- Completed, result not reported13141%
- Ongoing6119%
- Status unknown4715%
- Stopped: other or unclear3310%
- Met its primary endpoint3110%
- Stopped: enrollment or feasibility82%
- Missed its primary endpoint52%
- Stopped: sponsor or business decision31%
- Stopped: safety21%
- Stopped: funding21%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Feb 1, 2021 | Characterizing mmp12 in sputum and its relationship to emphysema and inflammatory endotypesHyperpolarized XENON-129 | St. Joseph'S Healthcare Hamilton | Pending |
| Nov 30, 2015 | An open-label, multicenter study to evaluate the long-term safety of weekly intravenous alpha1-proteinase inhibitor (human), modified process 60 mg/kg in…Prolastin-c | Grifols | Ongoing |
| Sep 18, 2013 | "a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of two dose regimens (60mg/kg and 120mg/kg) of weekly intravenous…Prolastin-c | Grifols | Closed |
FDA Orphan Designations
Approved first, then open designations, newest first| Dec 2, 1987 | ProlastinFor chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable… | Bayer Corporation | Approved |
| Jan 18, 2017 | Hyaluronic acidTreatment of emphysema due to alpha1-antitrypsin deficiency. | Gerard M. Turino, MD | Designated |
| Jan 29, 2010 | alpha1 proteinase inhibitor (human)Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency. | Grifols Therapeutics, Inc. | Designated |
| Mar 19, 2002 | Hyaluronic acidTreatment of emphysema in patients due to alpha-1 antitrypsin deficiency | CoTherix | Designated |
| Aug 28, 2001 | Recombinant human alpha-1 antitrypsin (rAAT)To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasis | AiroMedica LLC | Designated |
| Nov 24, 1999 | Alpha1-proteinase inhibitor (human)For slowing the progression of emphysema in alpha1-antitrypsin deficient patients. | CSL Behring L.L.C. | Designated |
| May 19, 1999 | Transgenic human alpha 1 antitrypsinTreatment of emphysema secondary to alpha 1 antitrypsin deficiency. | PPL Therapeutics (Scotland) Limited | Designated |
Medicines Authorised in the EU
Newest first| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Aug 20, 2015 | Respreezaalpha1-proteinase inhibitor (human) | CSL Behring GmbH | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA